Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Q2 2025 value amounting to -$5000.0.

  • Cartesian Therapeutics' Other Non Operating Income fell 10171.23% to -$5000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$449000.0, marking a year-over-year decrease of 14544.53%. This contributed to the annual value of $606000.0 for FY2024, which is 1230.1% down from last year.
  • As of Q2 2025, Cartesian Therapeutics' Other Non Operating Income stood at -$5000.0, which was down 10171.23% from -$444000.0 recorded in Q4 2024.
  • Cartesian Therapeutics' 5-year Other Non Operating Income high stood at $508000.0 for Q1 2024, and its period low was -$444000.0 during Q4 2024.
  • For the 5-year period, Cartesian Therapeutics' Other Non Operating Income averaged around $95875.0, with its median value being $84500.0 (2022).
  • Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Other Non Operating Income was 210000.0% (2022), while the steepest drop was 64285.71% (2022).
  • Cartesian Therapeutics' Other Non Operating Income (Quarter) stood at $9000.0 in 2021, then skyrocketed by 1844.44% to $175000.0 in 2022, then plummeted by 135.43% to -$62000.0 in 2023, then plummeted by 616.13% to -$444000.0 in 2024, then skyrocketed by 98.87% to -$5000.0 in 2025.
  • Its Other Non Operating Income was -$5000.0 in Q2 2025, compared to -$444000.0 in Q4 2024 and $250000.0 in Q3 2024.